Etripamil NS
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Supraventricular Tachycardia
Conditions
Paroxysmal Supraventricular Tachycardia
Trial Timeline
Dec 11, 2023 → Jun 30, 2027
NCT ID
NCT05763953About Etripamil NS
Etripamil NS is a phase 2 stage product being developed by Milestone Pharmaceuticals for Paroxysmal Supraventricular Tachycardia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05763953. Target conditions include Paroxysmal Supraventricular Tachycardia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05763953 | Phase 2 | Recruiting |
| NCT04072835 | Phase 3 | Completed |
Competing Products
20 competing products in Paroxysmal Supraventricular Tachycardia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |